Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).
Morris Sherman, MD
Advertisement
Articles by Morris Sherman, MD
Advertisement
Latest Updated Articles
Dr. Sherman on the Role of Regorafenib in Liver CancerPublished: January 14th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5